This article was originally published in The Gray Sheet
CMS seeks comments by Oct. 31 on whether Advanced Medical Optics' Tecnis intraocular lens should qualify for a new technology IOL payment under the ambulatory surgical system. AMO submitted additional information on the clinical relevance of Tecnis' increased contrast sensitivity this year, after CMS rejected the firm's application in 2004 for failing to show that patients benefited from the design improvements. AMO also provided more studies and a meta-analysis. If CMS approves the application, Tecnis will be reimbursed at a $50 premium over standard IOLs...
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.